HOME
NATION
NATION (OPINION)
BUSINESS & ECONOMY
INTERNATIONAL
SCIENCE & TECHNOLOGY
ENTERTAINMENT
LIFESTYLE & FASHION
SPORTS
TRAVEL
NATION
NATION (OPINION)
BUSINESS & ECONOMYINTERNATIONAL
SCIENCE & TECHNOLOGY
ENTERTAINMENT
LIFESTYLE & FASHION
SPORTS
TRAVEL
MORE STORIES Haryana opposition suspended for rest of session President asks parties to pass women's bill BJP parliamentary party to meet Tuesday Sonia Gandhi, Nooyi in Asia's 8 top power women Hot Gigs in Town Pakistan deserved much better, says Charlesworth Jet Airways offers discount for women in March Soren rules out change in tribal land right acts Training women to become future leaders Space taxis: Bold new era or death of manned exploration?
© 2008-2010 Dmanewsdesk.com
- All Rights Reserved.
- All Rights Reserved.
New AIDS vaccine ready for trials
July 1, 2009
Toronto: The Canadian University of Western Ontario has developed a new HIV/AIDS vaccine that is ready for human trials.
The vaccine called SAV001H has been developed by the university at London, about 160 km from here, in collaboration with Sumagen Canada, a subsidiary of the Korean pharmaceutical company.
In a statement Tuesday, Sumagen Canada said it has submitted an application to the US Food and Drug Administration (FDA) to begin the first phase of trials of the vaccine on human beings.
Chil-Yong Kang, a professor at the university, said they have completed safety and immunogenicity studies of the vaccine on animals. Immunogenicity measures the ability of a drug or vaccine to provoke an immune response in the body.
Trials of the new vaccine on animals have reportedly resulted in good anti-body reactions with no adverse effects.
Numerous trials have been carried out by pharmaceutical companies to develop vaccines since the AIDS virus was recognized in 1983, but no commercialised vaccine has been developed so far.
Sumagen Canada has secured patents for the vaccine in over 70 countries, including the US, the European Union and Korea.
It said the phase one clinical trials of the vaccine will double check its safety on HIV positive volunteers. The phase two trials would assess the immunogenicity of the vaccine.
Sumagen Canada said it is ready for clinical trials in the US as soon the FDA approval is granted.
The University of Western Ontario and the city of London have been short-listed by the Canadian government to set up an $88 million HIV vaccine manufacturing facility, which will be partly funded by the Bill and Melinda Gates Foundation.
Just last week Canadian scientists had announced a major breakthrough in AIDS treatment by saying that they have found where the HIV virus hides in the human body.
Currently, AIDS patients have to take a cocktail of up to five to six drugs to prolong their life up to 13 years.
There are over 33 million HIV patients worldwide, with 2.7 million more getting infected each year.
The vaccine called SAV001H has been developed by the university at London, about 160 km from here, in collaboration with Sumagen Canada, a subsidiary of the Korean pharmaceutical company.
In a statement Tuesday, Sumagen Canada said it has submitted an application to the US Food and Drug Administration (FDA) to begin the first phase of trials of the vaccine on human beings.
Chil-Yong Kang, a professor at the university, said they have completed safety and immunogenicity studies of the vaccine on animals. Immunogenicity measures the ability of a drug or vaccine to provoke an immune response in the body.
Trials of the new vaccine on animals have reportedly resulted in good anti-body reactions with no adverse effects.
Numerous trials have been carried out by pharmaceutical companies to develop vaccines since the AIDS virus was recognized in 1983, but no commercialised vaccine has been developed so far.
Sumagen Canada has secured patents for the vaccine in over 70 countries, including the US, the European Union and Korea.
It said the phase one clinical trials of the vaccine will double check its safety on HIV positive volunteers. The phase two trials would assess the immunogenicity of the vaccine.
Sumagen Canada said it is ready for clinical trials in the US as soon the FDA approval is granted.
The University of Western Ontario and the city of London have been short-listed by the Canadian government to set up an $88 million HIV vaccine manufacturing facility, which will be partly funded by the Bill and Melinda Gates Foundation.
Just last week Canadian scientists had announced a major breakthrough in AIDS treatment by saying that they have found where the HIV virus hides in the human body.
Currently, AIDS patients have to take a cocktail of up to five to six drugs to prolong their life up to 13 years.
There are over 33 million HIV patients worldwide, with 2.7 million more getting infected each year.
Business & Economy
Inflation to cool down in 2 months: Montek
Sonia Gandhi, Nooyi in Asia's 8 top power women
Haryana opposition suspended for rest of session
Jet Airways offers discount for women in March
Delhi Metro makes special arrangements for Commonwealth Games
LIC expects Rs.176,000 crore premium income this fiscal
Women to pilot AI's March 8 Mumbai-New York flight
Minister Sachin wants to 'Pilot' IT revolution in northeast
Twitter achieves 10 bn tweets, expects 20 bn by July
A new Manmohan Singh takes a bow
Industrialist G.P. Birla dead
BSNL to scrap Rs 35k cr tender
UP has no funds for stampede victim: Mayawati
PwC launches HR service, Saratoga, in India
Montek on UN climate change financing group
Lyondell setback unlikely to faze Ambani
Ashok Leyland may get into car manufacturing with Nissan
Purple cabbage, seedless cucumber on Games platter
Air India, IndiGo get new Airbus A320 aircraft
We hope to be a game changer in movie business: Anil Ambani
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
